Barinthus Bio Announces Q1 2026 Results and Mid-2026 Merger with Clywedog Therapeutics

Barinthus Biotherapeutics (NASDAQ: BRNS) announced its Q1 2026 financial results and provided a significant update on its proposed merger with Clywedog Therapeutics Inc. The transaction is expected to close in mid-2026, after which the combined company will be renamed Clywedog Therapeutics Holdings, Inc., trading under the ticker 'CLYD'. The merger aims to create a differentiated pipeline focused on autoimmune and metabolic diseases. Financially, Barinthus reported cash and equivalents of $67.2 million as of March 31, 2026, with a net loss of $5.5 million for the quarter—a significant reduction from the $19.6 million loss in the prior year period. The company also highlighted progress in its Phase 1 AVALON trial of VTP-1000 for celiac disease, with multiple ascending dose data expected in the second half of 2026. Additionally, Doug Swirsky was appointed as CFO, effective May 1, 2026. The combined company's cash runway is projected to extend through 2027.